BACKGROUND
There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who expe...
Toshifumi Yamaguchi, R. Kawabata, Y. Akamaru et al.· Gastric Cancer· 0 citations
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
Although cisplatin-based neoadjuvant chemotherapy is the standard for resectable esophageal squamous cell carcinoma in Japan, some patients are unfit due to age, renal, or cardiac dysfunction. No established treatment option exists for cisplatin-unfit...
Y. Ishizuka, Toru Kadono, Akitoshi Hakoda et al.· Diseases of the esophagus· 0 citations
Esophagectomy following induction chemoradiotherapy was associated with greater long-term weight loss and impaired nutritional recovery compared with surgery following chemotherapy alone, and these findings highlight the need for intensified nutritional surveillance and intervention in patients treated with preoperativ...
K. Sugimura, Koji Tanaka, T. Sugase et al.· Esophagus· 0 citations
Postoperative intervention with ONS did not seem to improve the prognosis of patients receiving adjuvant S-1 treatment, and the number of S-1 courses was a prognostic factor.
Y. Yanagimoto, T. Tsujinaka, Junji Kawada et al.· Anticancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.